Eli Lilly has submitted its oral GLP-1 drug orforglipron to the Food and Drug Administration for type 2 diabetes, the company confirmed in its second-quarter results. The same molecule was approved on April 1 for chronic weight management under the brand name Foundayo.
The filing matters for a reason that has little to do with efficacy. Orforglipron is a small molecule, not a peptide, and that difference reshapes what manufacturers can produce at scale after several years in which shortages of injectable GLP-1 drugs dominated patient experience.
